News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I (World)
Ascendis Announces Dosing Of Subjects In Phase I Trial Of Transcon PTH 9/26/2017
Kymab And Seattle Children's Research Institute Publish Impressive Results Using Kymab’s KY1005 In A Model Of Acute Graft Versus Host Disease (Agvhd) In Science Translational Medicine 9/22/2017
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon 9/22/2017
PharmaMar Starts Clinical Studies With A New Compound –PM14- In Patients With Solid Tumors 9/20/2017
Roche (RHHBY) Slammed With Partial Holds for Two Combo Cancer Trials 9/20/2017
Immuron Highlights Recent Milestones In Quest To Effectively Treat Multiple Forms Of Fatty Liver Diseases That Impact Millions 9/19/2017
TRANSGENE (ENX:TNG): First Patient Treated In A Phase Ib/II Trial Of TG4001 In Combination With Avelumab In HPV-Positive Cancers 9/19/2017
Karus Therapeutics Announces First Cancer Patients Dosed With KA2507, A Small Molecule HDAC6-Selective Inhibitor, In A Phase I Clinical Trial 9/18/2017
FDA Calls Regeneron (REGN), Sanofi (SNY) Carcinoma Drug a Breakthrough 9/15/2017
Targovax Announces Start Of Patient Recruitment In Phase I/II Study With ONCOS-102 In Combination With Durvalumab In Patients With Advanced Peritoneal Malignancies 9/12/2017
AC Immune SA Completes Recruitment For Low-Dose Cohort In World's First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer's Disease-Like Characteristics In Individuals With Down Syndrome 9/12/2017
Cascadian Therapeutics (ONTY) Release: Tucatinib Data In Multiple Tumor Types Presented At The European Society For Medical Oncology (ESMO) 2017 Congress 9/11/2017
ObsEva (OBSV) Announces Presentation Related To Its PGF2alpha Receptor Antagonist At ACCP 2017 Annual Meeting 9/11/2017
BeiGene (BGNE) Presents Preliminary Phase I Data For BGB-A317 In Multiple Solid Tumors At The ESMO 2017 Congress 9/11/2017
BeiGene (BGNE) Presents Preliminary Phase I/II Clinical Data On PARP Inhibitor BGB-290 In Patients With Advanced Solid Tumors At The European Society For Medical Oncology 2017 Congress 9/8/2017
ASLAN Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 9/7/2017
Advanced Accelerator Applications And FUJIFILM RI Pharma Announce First Patient In Bridging Study In Japan For Lutetium Lu 177 Dotatate* (Lutathera) 9/6/2017
Sanford Burnham Prebys Medical Discovery Institute And Daiichi Sankyo Announce Enrollment Of First Subject In A Phase I Clinical Trial Of DS-1211 In Healthy Volunteers 9/6/2017
Sanofi (SNY) Quietly Ends Its Zika Vaccine Project 9/5/2017
ProQR Therapeutics (PRQR)’s Drug Candidate QRX-421 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 9/5/2017
EnGeneIC Pty Ltd Announces Publication In The Lancet Oncology Of First Clinical Study Employing EDV Nanocell Platform to Enable microRNA Replacement Therapy 9/5/2017
Aelix Therapeutics Enrolls First Patient In Company’s Initial Therapeutic HIV Vaccine Clinical Trial 9/5/2017
Investors Wait with Bated Breath for AstraZeneca PLC (AZN)'s Cancer Trial Data Next Week 9/1/2017
Heptares Release: First Subject Dosed In Phase I Clinical Study Of Novel Selective MUSCARINIC M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease 9/1/2017
Sosei: First Subject Dosed In Phase1 Clinical Study Of Novel Selective Muscarinic M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease 9/1/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I Clinical Trial Of Selective PI3Kd Inhibitor HMPL-689 In Lymphoma Patients In China 8/29/2017
ProQR Therapeutics (PRQR) Completes Dosing Of Cystic Fibrosis Patients In QR-010 Phase Ib Trial 8/29/2017
Phase I Trials For Two Novel Treatments Of Obesity And/Or Diabetes Initiated By Zealand Pharma  (ZEAL.CO) Partner Boehringer Ingelheim 8/22/2017
Boehringer Ingelheim: Advancing Anticoagulation Care With New Data At ESC Congress 2017 8/21/2017
U.S. Department Of Defense To Conduct Studies Of Pluristem Therapeutics (PSTI)’s PLX-R18 In A New ARS Project For Use Before Radiation Exposure 8/16/2017
CARsgen Therapeutics Launches First-In-Class Anti-Claudin18.2 CAR-T Clinical Trial 8/10/2017
Theravance Biopharma (TBPH) Reports Encouraging Data From First Cohort Of Patients In Phase Ib Clinical Trial Of TD-1473 In Ulcerative Colitis 8/9/2017
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients 8/8/2017
4 Clinical Projects Shelved From Pfizer (PFE)’s Pipeline 8/3/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer 8/2/2017
First Human Subject Enrolled In Lumosa (6535.TWO)' LT3001 Trial 8/1/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 8/1/2017
FDA Calls Roche (RHHBY)'s Leukemia Drug a Breakthrough 7/31/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 7/31/2017
Oncolytics Biotech (ONC.TO) To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress 7/26/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer 7/26/2017
ORYZON Genomics Presents Final Data On The Phase I Trial With ORY-2001 At The Alzheimer's Association International Conference (AAIC-2017) 7/24/2017
NovoCure Announces A Phase Ib Clinical Trial To Evaluate The Safety Of Marizomib And Temozolomide In Combination With Optune® As Adjuvant Therapy In Patients With Glioblastoma 7/24/2017
Johnson & Johnson (JNJ) Announces Encouraging First-In-Human Clinical Data For Investigational HIV Preventive Vaccine 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
Celyad Announces Initiation Of The SHRINK Trial 7/20/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer 7/19/2017
Ascentage Pharma Approved To Start China Trial Of Apoptosis Drug 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
CStone Pharma Release: China's First Fully Human, Full-Length Anti-PD-L1 Monoclonal Antibody Receives Approval To Initiate Clinical Trials By The China Food And Drug Administration 7/17/2017
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies 7/11/2017
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
ProQR Therapeutics B.V. (PRQR)’s Drug Candidate QRX-411 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 7/5/2017
eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy Into First Oncology Clinical Studies 6/30/2017
Pharmaleads Reports Positive Phase I SAD Data With Its Dual Enkephalinase Inhibitor (DENKI) PL265 For The Treatment Of Neuropathic Pain 6/29/2017
Pharmaleads Reports Positive Phase I SAD Data With Its Dual Enkephalinase Inhibitor (DENKI) PL265 For The Treatment Of Neuropathic Pain 6/29/2017
BeiGene (BGNE) Presents Preliminary Phase I Data On BGB-A317 In Patients With Hepatocellular Carcinoma At The ESMO 19th World Congress On Gastrointestinal Cancer 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
NeuroVive (NVP) And Yungjin Pharmaceutical Company Ltd. Start Clinical Development In Genetic Mitochondrial Disease 6/27/2017
Ablynx (ABLYF) Initiates A Single And Multiple Dose Phase I Study Of Caplacizumab In Healthy Japanese Subjects 6/26/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
uniQure (QURE) Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress 6/23/2017
Summit Therapeutics Presents Data From Phase I Clinical Programme Of Ezutromid At The EPNS Congress 6/22/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
Evogene Ltd. (EVGN) Announces Positive Results In Insect Control Seed Trait Program And Advancement To Phase-I Of First Toxin Against Western Corn Rootworm 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
ADC Therapeutics Presents First Clinical Data From Its Novel Antibody-Drug Conjugate ADCT-402 At The International Conference On Malignant Lymphoma 6/19/2017
Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial 6/19/2017
Porton Biopharma Gains Approval To Advance Next Generation Anthrax Vaccine 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
BeiGene (BGNE) Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The 14th International Conference On Malignant Lymphoma And Announces Additional Planned Global Registrational Trials For BGB-3111 6/16/2017
ADC Therapeutics Presents Interim Data From The First Clinical Study Of Its Novel Antibody-Drug Conjugate ADCT-301 At The 14-ICML 6/16/2017
Generon (Shanghai) Corporation Ltd. Announces The Initiation Of A Phase I Clinical Study For A-337, A CD3-Activating Bi-Specific Antibody Targeting Epcam To Treat Solid Tumors 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Innate Pharma (IPH.PA ) Release: Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
Innate Pharma (IPH.PA ) : Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome 6/14/2017
BeiGene (BGNE) Presents Updated Phase I Data On BTK Inhibitor BGB-3111 In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At The 14th International Conference On Malignant Lymphoma 6/14/2017
Enyo Pharma Announces Successful Completion Of EYP001 First In Man Phase I Study 6/13/2017
Herantis Pharma's Clinical Study With CDNF In Parkinson's Disease Authorized In Finland, Company Expands On Development Plan 6/12/2017
Basilea (BSLN.SW) Announces Clinical Study Agreement With Adult Brain Tumor Consortium To Explore BAL101553 In Newly Diagnosed Glioblastoma 6/12/2017
ASLAN Announces TD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 6/12/2017
NeuroDerm (NDRM) Presents Six Posters At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 6/8/2017
ProQR Therapeutics B.V. (PRQR) To Present QR-010 Data At The European Cystic Fibrosis Society Conference And Provides An Update On The Ongoing Phase Ib Trial 6/8/2017
miRagen To Present MRG-106 Phase I Clinical Trial Data At The International Conference On Malignant Lymphoma 6/8/2017
ObsEva (OBSV) Announces The Completion Of A Phase I PK/PD Clinical Trial Evaluating Different Doses Of OBE2109 And Add-Back Therapy 6/7/2017
AFFiRiS AG Announces Top Line Results Of First-In-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity And Safety Profile In Parkinson's Disease Patients 6/7/2017
Adocia Announces Positive Topline Results From A Meal-Test Clinical Study Of Biochaperone Combo In People With Type 2 Diabetes 6/7/2017
Basilea (BSLN.SW) Announces Presentation Of Interim Phase I/IIa Clinical Data With Anticancer Drug Candidate BAL101553 At ASCO Meeting 6/6/2017
Targovax Presents Further Positive Clinical Data From TG01 Phase I/II Trial At 2017 ASCO Annual Meeting 6/6/2017
Nanobiotix : Promising Data From Phase I/II Head And Neck Cancer Trial With NBTXR3 Presented At The ASCO's Annual Meeting 6/5/2017
Adaptimmune (ADAP) Announces An Oral Presentation On Data From NY-ESO Study In Synovial Sarcoma And Four Trials In Progress Posters At The ASCO Annual Meeting 6/5/2017
HalioDx: Immunosign Gene Signature Assesses LTX-315 Ability To Turn 'Cold' Tumors 'Hot' At ASCO 2017 6/5/2017
Spectacular Data Posted for Novartis AG (NVS)'s Next Generation CAR-T Drug 6/2/2017
Orexo (ORXOF) Receives USD 2.5 Million Milestone Payment From AstraZeneca PLC (AZN) As OX-CLI Advances Into Clinical Trials 6/2/2017
Global Kinetics Corporation And Parkinson's Disease Foundation Announce First Patient Enrolled In APPRISE Clinical Study For Optimization Of Parkinson's Treatment 6/1/2017
Debiopharm Announces Results From Phase I Dose-Escalation Study Of Debio 1347/CH5183284 6/1/2017
Adocia Launches First-in-Man Clinical Study Of BioChaperone Glucagon 6/1/2017
Lamellar Biomedical Ltd Recruits First Patients Into Clinical Study Assessing LAMELLEYE For Treatment Of Dry Eye Disease 5/31/2017
Medical Prognosis Institute's Spinout Oncology Venture's Second Drug Candidate In The Clinic - First Multiple Myeloma Patient In Study With APO010, An Immuno-Oncology Drug 5/31/2017
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From The FDA For QR-110 For Leber’s Congenital Amaurosis Type 10 5/31/2017
Imcyse Obtains Authorization To Launch Phase Ib Trial In Type 1 Diabetes 5/31/2017
Atlantic Healthcare Develops Tablet Formulations Of Alicaforsen To Treat Crohn's Disease And Ulcerative Colitis 5/30/2017
Mallinckrodt (MNK) Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse 5/26/2017
Hovione Announces Start Of Phase l Clinical Trial Of HY02, A Proprietary Minocycline Sterile Ointment To Treat A Subset Of Anterior Ocular Inflammation 5/25/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
BioLineRx Announces Regulatory Submission For Phase Ib Trial Of BL-8040 In Combination With Atezolizumab In AML 5/22/2017
Regeneus (RGS.AX) Positive Clinical Trial Results For Progenza 5/22/2017
ADC Therapeutics Doses First Patient In A Phase I Clinical Trial Of ADCT-502 In Patients With Advanced Solid Tumors With HER2 Expression 5/19/2017
ObsEva (OBSV) Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022 5/18/2017
Patient Treatment Commences In Cynata’s World First Clinical Trial 5/17/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
Probiodrug AG Announces Acceptance Of PQ912 Pharmacology Paper By Peer Reviewed Journal 5/16/2017
Zealand Pharma  (ZEAL.CO) Discloses Amylin As The Biological Target Under Their 2014 Agreement With Boehringer Ingelheim 5/11/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Sierra Oncology Receives Clearance To Enhance Ongoing Clinical Trials For SRA737 5/10/2017
Targovax Recruits First Patient Into First ONCOS-102 /Checkpoint Inhibitor Melanoma Study 5/10/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease 5/9/2017
Botanix Commences First Clinical Study For BTX 1503 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
SGS Life Science Services (SGSN) Clinical Research Announces Results Of First-In-Human Studies Using Novel Virus As Experimental Challenge Agent 5/5/2017
Hookipa Biotech Presents Positive Data From Phase I First-In-Human Trial Of Vaccine Against Cytomegalovirus 5/4/2017
YiSheng BioPharma Starts China Phase I Trial Of Immuno-Oncology Candidate 5/4/2017
YiSheng BioPharma Starts Enrollment In Phase I Immuno-Oncology Clinical Trial Of YS-ON-001 In Patients With Advanced Solid Tumors 5/1/2017
ProQR Therapeutics B.V. (PRQR) Announces Clearance Of IND Application To Start Clinical Trial For QR-110 In Leber’s Congenital Amaurosis Type 10 Patients 4/27/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Amazentis Announces Successful Phase IA/IB Study Results In Healthy Elderly Subjects With The Food Metabolite Urolithin A 4/27/2017
First Patient Treated In Turnstone Biologics's Lung Cancer Trial Combining Novel Viral Cancer Therapy With Approved Checkpoint Inhibitor 4/26/2017
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers 4/24/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Publication Of Peer-Reviewed Paper From Positive Clinical Trial Of Milciclib In Patients With Refractory Solid Tumours 4/21/2017
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Of The Positive YELIVA Phase I Study Results In Advanced Solid Tumors 4/20/2017
BTG plc (BTG.L) Release: First European Patients Treated With Dc Bead Lumi Radiopaque Drug-Eluting Beads 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/19/2017
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development 4/11/2017
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine 4/11/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Galapagos (GLPG.BR) Doses First Psoriatic Arthritis Patient With Filgotinib 4/6/2017
Asceneuron Receives Regulatory Approval For Phase I Healthy Volunteer Study Of Oral Tau Inhibitor 4/6/2017
Cardiome Pharma Corp. (COM.TO)'s Partner SteadyMed (STDY) Announces Successful Completion Of Trevyent Clinical Validation Study 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
ABIVAX Initiates Clinical Trial (ABX464-005) To Evaluate The Effect Of ABX464 On HIV-Reservoirs In HIV Patients 4/5/2017
Common Antibiotic May Help To Prevent Or Treat PTSD, University of Zurich Study Reveals 4/4/2017
RedHill Biopharma (RDHL) Receives FDA Orphan Drug Designation For YELIVA For The Treatment Of Cholangiocarcinoma 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
Biovica Release: DiviTum Results In Blockbuster Drug Study Presented At AACR 4/3/2017
ESSA Pharma Provides Clinical Study Update And Announces Presentations At The AACR Annual Meeting 4/3/2017
Clinical Results Presented From Prothena (PRTA)’s Phase Ib Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-Synuclein In Patients With Parkinson’s Disease 4/3/2017
Oncodesign SA Presents Its Latest Scientific Developments At The AACR Annual Global Meeting On Oncology 4/3/2017
Phase I Clinical Trial Completes Using Cell Line Expertise At Cobra Biologics Ltd. 4/3/2017
DBV Tech, BioNet-Asia And Geneva University Hospitals Announce Phase I Trial Results Of Viaskin rPT In Pertussis Booster Vaccination 3/31/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
JHL Biotech Doses First Patient In JHL1101 Phase I European Trial 3/29/2017
Compugen Ltd. (CGEN) Announces Lead Therapeutic Candidate COM902 For CGEN-15137/TIGIT Immuno-Oncology Program 3/28/2017
MediGene AG (MDGEF.PK): Announces Target And Outlines Design For Its First Clinical Trial In TCR Cancer Immunotherapy (MDG1011) 3/23/2017
Intec Pharma Initiates Phase I Trial Of Accordion Pill For Cannabinoid Therapies 3/22/2017
Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102 3/21/2017
WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5 3/21/2017
Replicel Life Sciences's Phase I Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints 3/14/2017
Lung Therapeutics Doses First Patient In Phase I Clinical Trial Of LTI-01 In Australia And New Zealand 3/14/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/8/2017
Renown Pharma Announces Successful Results Of Apomorphine Sub-Lingual Spray Pharmacokinetic Study To Treat "OFF" Episodes In Parkinson's Patients 3/7/2017
Herantis Pharma's Clinical Study With Lymfactin Advances To High Dose Level 3/7/2017
Trillium Therapeutics Provides Additional Details On ASCO-SITC Conference Presentation On TTI-621 2/24/2017
Acticor Biotech Has Selected Its Contract Research Organization To Manage Clinical Study Phase I 2/23/2017
Boston Scientific (BSX) Sinks After Recalling All Lotus Heart Valves 2/23/2017
hVIVO Services Limited Notes The Initiation Of A Phase I Clinical Trial With AGS-V, A Mosquito-Borne Disease Vaccine Candidate 2/21/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia 2/14/2017
Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 2/14/2017
Hutchison China MediTech (Chi-Med): Initiates Phase I Of Novel FGFR Inhibitor HMPL-453 2/14/2017
Hutchison China MediTech (Chi-Med) Launches Phase I Trial Of Novel FGFR Inhibitor In Australia 2/14/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Vyome Announces Top-Line Results From Phase 1 Study Of VB-1953 For Patients With Facial Acne Vulgaris 2/7/2017
No Looking Back: Cellectis (CLLS) Preps for Cutting-Edge 'Off-the-Shelf' CAR-T Trial 2/7/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Auris Med (EARS) Expands Clinical Development Pipeline With Intranasal Betahistine For The Treatment Of Meniere's Disease And Vestibular Vertigo 2/6/2017
Lysogene Receives Orphan Drug Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/3/2017
Phase I Clinical Data Of ABX464, ABIVAX's First-In-Class Anti-HIV Drug, Published In Two Articles In Peer-Reviewed Journals 2/3/2017
Auris Med (EARS) Expands Beyond Cochlear Therapies To Include Vestibular Therapy: Intranasal Betahistine, AM-125 2/3/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta 1/19/2017
Lysogene Release: Biotech Receives Rare Pediatric Disease Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Hutchison China MediTech (Chi-Med) Release: Company Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium 1/16/2017
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017
Hutchison China MediTech (Chi-Med) Release: Company Initiates HMPL-523 Clinical Trials In Hematological Cancer In China 1/10/2017